A LEGACY OF IMPACT & INNOVATION

MD Anderson’s fourth full-time president continues quest to end cancer
CONTENTS
IN THIS ISSUE

3 TIME 100
Jim Allison, Ph.D., makes list of world’s most influential people.

7 Still riding strong
Texas 4000 alumna remains dedicated to fight to end cancer.

14 Peace of mind
Florida donor provides for unmet needs of patients and families.

15 Springtime fun
Kids and parents enjoy festivities at Bunny Hops and Photo Ops.

6 Neurofeedback can ease symptoms of neuropathy
Pilot study in Cancer

SECTIONS
3 News Makers
7 Moon Shot Momentum
8 Donors Make a Difference
12 Among Friends
13 Spotlight
14 Philanthropy in Action
15 Survivors Say
Back Cover: iPromise

UPCOMING EVENTS
JULY
19: Houston
Third Party Appreciation Luncheon
24: Aspen, Colorado
Making Cancer History® Seminar

SEPTEMBER
12: Houston
Julie and Ben Rogers Award for Excellence
14: Dallas
A Conversation With a Living Legend®: Santiago Calatrava, Ph.D.
20: Atlanta
Making Cancer History® Seminar

OCTOBER
16: Houston
Brown Foundation Award for Excellence in Oncology Nursing

NOVEMBER
7-8: Houston
Board of Visitors Reception and Annual Meeting
15: Houston
A Conversation With a Living Legend®: Rich Kinder

ACCESS ANSWERS
To become a patient: Call 877-632-6789 or fill out the self-referral form at www.mdanderson.org.

For more information, please visit www.mdanderson.org/gifts or call 800-525-5841.

Download Promise at www.mdanderson.org/Promise.

If you do not want to receive certain fundraising communications from MD Anderson, please visit our website at www.mdanderson.org/FundraisingOptOut or contact us at 855-344-5272.

PROMISE
The University of Texas MD Anderson Cancer Center Development Office - Unit 705 P.O. Box 301439 Houston, TX 77230-1439 713-792-3450 800-525-5841 mdanderson.org/gifts promise@mdanderson.org

Marshall Hicks, M.D.
President Ad Interim

Todd Pullin
Senior Vice President for Institutional Advancement

Patrick Mulvey
Vice President for Development

Brette Peyton
Executive Director, Public Relations

Sarah Watson
Editor, Program Director Development Communications

Allison Schaffer
Assistant Editor Senior Communications Specialist

Leslie Friedman
Senior Communications Specialist

Marily Scarica
Senior Communications Designer

Contributing Writers
Sarah Kettles
Lany Kimmons
Brendan Locke
Scott Merville
Charlie Nater
Karlee Steele

ON THE COVER:
MD Anderson salutes its fourth full-time president, Ronald DePinho, M.D., as he continues to pursue his passion for research. p. 4

JIM OLIVE

Comments? Suggestions? We welcome your perspective. Email us your thoughts: promise@mdanderson.org.
PHYSICIANS, RESEARCHERS ACCELERATE MISSION TO END CANCER

Board of Visitors members honor faculty efforts with endowed awards

BY ALLISON SCHAFFER

Dozens of MD Anderson physicians and researchers were in the spotlight April 18 at the President's Recognition for Faculty Excellence, an annual event that honors faculty members whose exceptional efforts have brought distinction to the institution. Among the many awardees, four received cash prizes endowed by members of the MD Anderson Cancer Center Board of Visitors (BOV).

The Jack and Beverly Randall Prize for Excellence in Cancer Research

Funded through an endowment established by BOV member Jack Randall and his wife, Beverly, in 2015, the Randall Prize honors creative faculty members who have shown uncommon foresight and ingenuity in the fight against cancer.

Nicholas Navin, Ph.D., associate professor, Genetics and Bioinformatics, and an Andrew Sabin Family Fellow, is the 2017 recipient of the Randall Prize. Navin, who focuses on understanding genome evolution in human cancers, received the $100,000 cash award for his seminal contributions in single-cell genomics and for groundbreaking research that established single-cell sequencing.

The Finneran Family Prize for Translational Research

William B. Finneran, a longtime BOV member, established the Finneran Family Prize in 2013 through a $1 million endowment. Leading faculty members in translational cancer research who apply findings from basic science to effective cancer therapies are eligible for the $50,000 cash prize.

Burton Dickey, M.D., professor and chair, Pulmonary Medicine, is the latest recipient of the Finneran Family Prize for Translational Research for exceptional productive translational work in lung epithelial biology. Dickey discovered a highly innovative drug to prevent and treat pneumonia, the second leading cause of death in cancer patients after cancer itself, and he is bringing the drug to clinic.

The Shirley Stein Scientific Endowed Research Award

Funded through an endowment established by Triple S-Steel/Gary Stein, a BOV member, the Stein family and longtime BOV member Regina Rogers, the Stein Award offers a cash prize for outstanding clinical research by faculty with limited project resources.

Sinchita Roy-Chowdhuri, M.B.B.S., Ph.D., assistant professor, Pathology, and Simona Shaitelman, M.D., assistant professor, Radiation Oncology, are co-recipients of the 2017 Shirley Stein Scientific Endowed Research Award. Roy-Chowdhuri is recognized for research in defining conditions to optimize the use of routine cytological specimens for multiplex DNA mutation testing. Her findings have improved the likelihood of obtaining a successful molecular test result from a patient's diagnostic pathology material. Shaitelman is honored for building the Lymphedema Screening Initiative in MD Anderson's Breast Center. Her pioneering work has led to the largest lymphedema screening program for breast cancer patients in the U.S.

TIME 100 TAPS IMMUNOTHERAPY PIONEER

Jim Allison, Ph.D., makes prestigious annual list

MD ANDERSON Chair of Immunology Jim Allison, Ph.D., whose pivotal insight to attack cancer by treating the immune system instead of the tumor revived cancer immunotherapy, has been named to the 2017 TIME 100. The list, in its 14th year, recognizes the world’s most influential individuals.

“Each year our TIME 100 list lets us step back and measure the forces that move us,” says TIME Editor-in-Chief Nancy Gibbs. “One way or another they each embody a breakthrough: They broke the rules, broke the record, broke the silence, broke the boundaries to reveal what we’re capable of.”

Allison’s breakthrough liberates the immune system to find and destroy cancer cells, an approach called immune checkpoint blockade. This new class of drugs is saving the lives of significant numbers of patients with a variety of advanced cancers and is transforming the course of cancer research.

“I’m grateful to TIME for recognizing the increasing importance of immunotherapy as a new pillar of cancer treatment,” says Allison, who also is executive director of the Immunotherapy platform, part of the institution’s Moon Shots Program™ (see page 7). “We’re in the early days of successful cancer immunotherapy. Our next step is to extend these treatments to benefit more patients, and our platform is intensely focused on making that a reality.”

SCOTT MERVILLE
A legacy of impact & innovation

MD Anderson’s fourth president turns focus to cancer research, advocacy

BY SARAH WATSON

MD Anderson salutes Ronald DePinho, M.D., in gratitude for his service as the institution’s fourth full-time president, Sept. 2011-March 2017. A visionary leader, DePinho leaves a legacy of historic innovation and global impact. Throughout his tenure, he set an ambitious agenda to recruit and retain world-class clinicians and researchers, speed technology transfer, develop national and international collaborations, and mobilize faculty and staff to effect significant change — in the way teams work, the way research is enabled, the way ideas are applied to create new treatments and digital solutions, and the way knowledge and expertise can inspire health policies that aim to reduce youths’ cancer risk.

As he resumes his passion for research, DePinho remains a champion of MD Anderson’s efforts in Making Cancer History®, conducting translational science to make a meaningful impact in the clinic and advocating for cancer research funding and effective health policy as vice chair of ACT for NIH: Advancing Cures Today, a nonpartisan effort to increase support for biomedical research. In addition, he will coordinate a global multi-sector effort to advance cancer care, particularly for the impoverished.

Having served on the Board of Visitors for nearly 25 years, it has been an honor and pleasure to work closely with Dr. DePinho during his tenure as president, as it was with Drs. LeMaistre and Mendelsohn. Dr. DePinho brought his quest to cure cancer to MD Anderson with great vision and enthusiasm. Worldwide, thousands of cancer patients’ lives have been saved and extended by MD Anderson’s skilled physicians and staff under Dr. DePinho’s leadership. We look forward to following his continued success with best wishes to him and his family.”

— HARRY LONGWELL, Past Chair, MD Anderson Cancer Center Board of Visitors

“During his tenure as president, Dr. DePinho’s positive impact on our institution and our nation will be felt for years to come. I, for one, am proud he always will be a member of our MD Anderson team.”

— MARSHALL HICKS, M.D., President ad interim
Dr. DePinho is an outstanding scientist who has tremendous passion for innovative research that will lead to better understanding, diagnosis, treatment and prevention of cancer. This was the main focus for his recruitment of leading investigators to MD Anderson, and for his bold Moon Shot and drug development research agendas for the institution. He greatly expanded our funding from both industry and philanthropy, at a time when federal grants no longer cover the majority of our research costs. And he promoted the continued growth of our national and international collaborative programs, bringing our expertise to patients and cancer programs worldwide.”

— JOHN MENDELSOHN, M.D.
Director, Sheik Khalifa Bin Zayed Al Nayan Institute for Personalized Cancer Therapy
MD Anderson President, 1996-2011

Ron DePinho is a great friend, a true innovator and one of the most dedicated individuals in the search for a cure for cancer. He was a driving force behind establishing the Andrew Sabin Family Fellowship Program at MD Anderson. It has been a pleasure to work with him as advocates for increased medical funding through ACT for NIH.”

— ANDY SABIN, MD Anderson Cancer Center Board of Visitors Member

Ron DePinho, M.D., updates MD Anderson supporters at an event in September 2012 formally announcing the launch of the Moon Shots Program™.
FOCUS ON EXECUTIVE LEADERSHIP
Hicks named president ad interim, Hahn becomes chief operating officer

IN MARCH, The University of Texas System Chancellor Bill McRaven appointed Marshall Hicks, M.D., as president ad interim of MD Anderson following the resignation of Ronald DePinho, M.D. Hicks has served as division head of Diagnostic Imaging since 2010. A member of MD Anderson’s faculty for almost 20 years, he is one of the institution’s senior and most experienced leaders.

Hicks is the author of more than 100 scientific publications and is former president of the Society of Interventional Radiology. Specializing in interventional radiology, he has been a collaborator in many clinical research studies of lung, liver, colon and head and neck cancers.

“T’m honored to serve as interim president,” says Hicks. “This extraordinary institution holds a special place in the hearts of its patients and their families, our outstanding faculty and trainees, our dedicated staff, the Houston community and people across the world.”

Joseph Steele, M.D., professor, Diagnostic Radiology and Interventional Radiology, is division head ad interim of Diagnostic Imaging until Hicks returns to his former position.

A search advisory committee will conduct a national search for a permanent president, aiming to recommend top candidates to the UT System Board of Regents by September 2017.

Deputy president, chief operating officer
In February, Stephen Hahn, M.D., former division head, department chair and professor of Radiation Oncology, was named deputy president and chief operating officer. He is responsible for managing day-to-day business, clinical and faculty matters.

“Since joining MD Anderson more than two years ago, I’ve had the pleasure of serving alongside our outstanding faculty,” says Hahn. “I look forward to working with the MD Anderson community to serve our patients.”

An internationally recognized leader in radiation oncology, Hahn joined MD Anderson from the University of Pennsylvania’s Perelman School of Medicine, where he was chair of Radiation Oncology from 2005 to 2014.

He is an active clinician with expertise in lung cancer and sarcoma. His research focuses on the molecular causes of the tumor microenvironment, particularly the study of chemical signals that go awry and the evaluation of proton therapy to improve efficiency of radiation therapy.

STUDY SHOWS NEUROFEEDBACK CAN EASE NEUROPATHY SYMPTOMS
Functional brain training seen as new tool for patients with chemotherapy-induced nerve damage

A TYPE of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced peripheral neuropathy (CIPN), according to an MD Anderson pilot study published in the journal Cancer.

CIPN is caused by damage to the nerves that control sensation and movement in arms and legs. It’s estimated to affect between 71 and 96% of patients one month after chemotherapy treatment, says Sarah Prinsloo, Ph.D., assistant professor of Palliative, Rehabilitation and Integrative Medicine Research. Symptoms include pain, burning, tingling and loss of feeling.

“We observed clinically and statistically significant reductions in peripheral neuropathy following neurofeedback techniques,” says Prinsloo, lead investigator of the study. “This research suggests that neurofeedback may be a valuable approach to reduce neuropathy symptoms and their impact.”

The study was funded by the American Cancer Society, the Rising Tide Foundation, the Hille Foundation and the National Center for Complementary and Integrative Health.
Launched in 2012, MD Anderson’s Moon Shots Program™ aims to significantly reduce cancer deaths and transform cancer care. Moon Shot™ teams pursue innovative projects prioritized for greatest patient impact, and specialized platforms provide infrastructure, systems and strategy. These efforts will help support all other cancer research at MD Anderson. Funding is from private philanthropy, institutional earnings, competitive research grants and commercialization of new discoveries. The Beau Biden Cancer Moonshot, led by former Vice President Joe Biden, aligns with the program to accelerate progress in the fight against cancer.

Private philanthropic commitments to the program total more than $435.1 million.

**MY MOON SHOT**

**SARAH KETTLES,** originally from Mansfield, Texas, lives in the San Francisco Bay area. She’s a 2013 alumna of Texas 4000, a program that cultivates University of Texas student leaders in the fight against cancer through a 4,000-mile bike ride from Austin to Anchorage, Alaska.

Camping on the John Muir Trail in a secluded meadow overlooking the Sierra Nevada Mountains, I was joined by a woman who also had decided to call the meadow home for the night.

We shared dinner and hot chocolate, watched the alpine glow dance across the mountains and talked about our lives.

I asked why she was spending a month to hike alone for 211 miles. Her answer: ‘To take advantage of the time I have left.’

She’d recently learned that her breast cancer treatments weren’t working. She was choosing to take advantage of the one year of good health in front of her.

I didn’t know it then, but her story was the driving force in my commitment to a 2017 Ironman® Triathlon, for her and for all the people in my life who’ve been affected by cancer.

I began my fight against cancer in 2013 when I rode with Texas 4000 and raised $330,000 with my teammates for cancer and support programs. I’ve since been a member of Texas 4000’s Grants Committee. During my second year, we decided to fund a seed grant for a promising research project at MD Anderson that lacked data to back it up. Texas 4000 was willing to take a chance, and two years later we received an astounding report. This research was on track to become a game-changer in targeted cancer treatments.

I’m registered for the Nov. 19 Ironman in Tempe, Arizona. I will swim 2.4 miles, ride 112 miles and run 26.2 miles to fight cancer.

I’m raising $10,000 for MD Anderson’s Moon Shots Program™ because I believe in research that pushes the envelope. The future of a world without cancer rests with researchers who are willing to take risks and try new things.

**WHAT’S YOUR MOON SHOT?**

Contact us at promise@mdanderson.org and tell us why MD Anderson’s Moon Shots Program is important to you.

**AREAS OF FOCUS:**
- B-cell lymphoma
- Breast cancer
- Chronic lymphocytic leukemia
- Colorectal cancer
- Glioblastoma
- High-risk multiple myeloma
- Human papillomavirus-related cancers
- Lung cancer
- Melanoma
- Myelodysplastic syndromes and acute myeloid leukemia
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer

**About the Adaptive Patient-Oriented Longitudinal Learning and Optimization (APOLLO) platform**

• Andrew Futreal, Ph.D., professor of Genomic Medicine

• Cynthia Powers, director of Ambulatory Work Standardization

APOLLO is a clinical framework to assure quality data by providing a structure that accelerates research-driven patient care. It has streamlined and standardized a process for:

• gathering high-quality biopsies and conducting biospecimen draws before, during and at the end of treatment

• preparing samples for deep genomic/molecular analysis and immune response monitoring

• storing results in the Translational Research Accelerator platform, which is the first and currently only truly integrated clinical and research data platform made for cancer research

APOLLO has been used successfully in leukemia, sarcoma and melanoma pilot projects. In the next two years, it is scheduled to conduct analyses in 2,100 patients enrolled on 28 high-priority clinical trials for lung, breast, colorectal, pancreas, ovarian and HPV-related cancers, as well as multiple myeloma, glioblastoma, lymphoma and sarcoma.

APOLLO has standard-changing potential. The platform will enable deep longitudinal molecular profiling of even the rarest cancers, populating the most comprehensive, patient-centric and clinically driven molecular cancer dataset anywhere.

**Private philanthropic commitments to the program total more than $435.1 million.**
DOCTOR’S DETERMINATION INSPIRES FAMILY DONATION

Jake and Nina Kamin Endowment honors intersecting legacies

BY CHARLIE NATER

Susan Smith didn’t have to look far for an institution that would honor her sister, Linda Chapman Golden, who lost her life to multiple myeloma. As a research data coordinator working with patients in clinical trials at MD Anderson, Smith witnessed for more than a decade how philanthropy helps doctors save lives. She met with Robert Orlowski, M.D., chair of Lymphoma/Myeloma, to discuss how myeloma patients might benefit from an endowment in her sister’s memory.

Orlowski, whose father, Marian Orlowski, M.D., was nominated for the 2004 Nobel Prize for research in proteasome activity, told Smith about some of the research going on in his lab. One focus area that sparked her interest is the development of preclinical cancer models to understand common genetic abnormalities of tumors. Through the genetic analyses of patient samples, Orlowski explained, researchers learn about the many subtypes of myeloma, which allows physicians to determine who gets what treatment, as quickly as possible. Collecting, processing, storing and analyzing these patient tumor samples, however, can be quite expensive, he added.

Smith also learned that when Orlowski was a postdoctoral fellow at Johns Hopkins School of Medicine, he found that cells die more quickly when put in contact with proteasome inhibitors. With this knowledge, he laid the groundwork for bortezomib, the first drug targeting the proteasome, now used to treat tens of thousands of patients with multiple myeloma.

“It was exciting to advance my father’s research from the lab to the patient,” says Orlowski. “I’m proud to have built upon his life’s work.” Orlowski’s determination to find enduring treatments inspired Smith to help establish, through her family’s Jake and Nina Kamin Foundation, the Jake and Nina Kamin Endowment for Multiple Myeloma Research in Memory of Linda Chapman Golden.

“For years, I got to witness how clinical trials helped patients in need of hope,” says Smith, who is now retired. “It’s my family’s desire to bring hope to patients at MD Anderson.”

UNFINISHED BUSINESS

Brothers donate allowance to brain cancer research in father’s memory

BY ALLISON SCHAFFER

Three brothers. One mission.

Parker, Harrison and Oliver Broach typically donate 10% of their allowance to a charitable cause of their choice.

“We want to give money and be nice,” says 7-year-old Oliver.

But most recently, the boys decided to pool all of their money — from allowances to Christmas gifts to little bits saved here and there — to support a cause that hits extremely close to home.

The Broach brothers donated $400.75 to support brain cancer research at MD Anderson through the Broach Foundation for Brain Cancer Research. Established by their mother, Jamie Broach Byrd, and their late father, James Broach, the Broach Foundation promotes funding for brain cancer research and education so that effective treatments, and ultimately a cure, can be found.

“We don’t want any other people to die,” says Parker, 10. “We want them to live longer and not be in so much pain.”

To date, the Broach Foundation has funded more than $4 million for brain cancer research.

“It was really heartwarming to see them save all this money, look outside of themselves and be willing to contribute to a cause to help others,” says Jamie. “I think James would be really proud of them.”

Harrison, 9, hopes his friends and other kids his age are inspired by their gift.

“They should do it too!” he says.

The Broach Foundation’s sixth annual Stand-Up for Brain Cancer gala, April 6 at the River Oaks Country Club in Houston, featured comedian Kevin Nealon, and raised more than $530,000 for brain cancer research.
In Full Swing

Cancer prevention efforts aim for greater reach at Shell Houston Open

By Allison Schaffer

As the official cancer center of the PGA TOUR, MD Anderson touches countless members of the golf community every year with a message of cancer prevention and a reminder of the dangers from continued exposure to the sun. From offering free sunscreen and UV-protectant sunglasses to providing shaded grandstands for sweltering golf fans, MD Anderson’s primary mission on the golf course is to prevent cancer from occurring in the first place.
MD Anderson and Topgolf have teamed up in hopes of taking cancer prevention efforts to even greater heights. MD Anderson is the official charity partner of Topgolf, a premier entertainment and event venue that offers point-scoring golf games for all skill levels, with more than 40 locations across the U.S. and U.K.

Through the summer, Topgolf will share cancer prevention messages at all locations nationwide. In July, the company will run a fundraising campaign, a first-of-its-kind initiative for Topgolf. Customers will have the opportunity to donate $5 to receive a $10 play coupon, with all funds going back to MD Anderson to support crucial cancer research and prevention programs.

Skin cancer is the most common cancer in the United States. It’s also one of the most preventable.

—TOM BUCHHOLZ, M.D.

This year, cancer prevention efforts expanded dramatically at the Shell Houston Open. MD Anderson dermatologists Saira George, M.D., assistant professor, Dermatology; Anisha Patel, M.D., assistant professor, Dermatology; and Sana Zahiruddin, M.D., resident, Dermatology, provided nearly 100 skin screenings, free to players, caddies and the public over the course of the week.

Cancer prevention experts including Therese Bevers, M.D., professor, Clinical Cancer Prevention, also were on hand to answer questions from tournament attendees about anything under the sun.

Golf fans found respite at MD Anderson’s Strike Through Cancer Pavilion and shaded grandstands near the 18th green. In addition to the 30-foot Strike Through Cancer Wall, the biggest attraction was the sunscreen station, upgraded this year to include a mirror to encourage thorough sunscreen application on faces, ears and necks.

“Skin cancer is the most common cancer in the United States,” says Tom Buchholz, M.D., executive vice president and physician-in-chief. “It’s also one of the most preventable. Over the past few years, we’ve educated millions of people on ways to reduce their risk for developing cancer. By having our expert dermatologists and cancer prevention specialists on-site at the course this year, I’m hopeful that even more people will take notice and take action.”

MD Anderson also had a presence at The PLAYERS Championship in Ponte Vedra Beach, Florida, and will be at the TOUR Championship in Atlanta, Georgia, in September.
To kick off Shell Houston Open festivities, the PGA TOUR WIVES ASSOCIATION donated $5,000 to MD Anderson Children’s Cancer Hospital to host a golf-themed party on March 28 for teen and young adult patients. Nearly a dozen patients headed to the Four Seasons hotel in downtown Houston, where they were treated to a night of fun in the Swing Suite, featuring two Topgolf simulators. They also enjoyed plenty of other games and food courtesy of the PGA TOUR Wives Association. Mark Rolfing, a cancer survivor and longtime NBC Sports/Golf Channel analyst, and his wife, Debi, were on hand, along with the PGATOUR wives.

The PGA TOUR wives pause for a photo with Mark and Debi Rolfing, center.
GETTING TO KNOW

Marsha Shields

BY SARAH WATSON

Marsha Shields, a lifelong resident of San Antonio, has been an active member of the MD Anderson Cancer Center Board of Visitors (BOV) since 2008. She currently serves as vice chair and will begin her two-year term as chair in September 2018. At that time, she will be the BOV’s second female chair and its first second-generation chair, following the tradition established by her father, BOV Life Member Red McCombs, 1995-1997 chair. Marsha wears many hats at McCombs Enterprises, which has interests in automobile dealerships, real estate, energy, multiple business entities and ranching.

She also is manager of McCombs Family Partners and president of the McCombs Foundation, which contributed $30 million to MD Anderson’s Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer in 2005. A melanoma survivor, Marsha co-chaired MD Anderson’s 75th anniversary gala committee in 2016 along with her husband, Hon. John H. Shields, helping raise more than $13.5 million for patient care and research initiatives. They have two grown children and two grandchildren.

What three words best describe what is most important in life?
Faith, family, friends.

What does it take to be a good leader?
The responsibility of leadership requires being a good listener, being teachable, being flexible, preparing a plan and executing it to completion.

What are your goals as BOV chair-elect?
I hope to identify and use the talents, gifts and knowledge of each member to enhance MD Anderson’s mission to end cancer.

In addition to your advocacy for MD Anderson, what do you do with your spare time?
I take delight in spending time with my family, especially our grandchildren. I enjoy reading, cooking and solving puzzles.

How did you become involved with the BOV?
I wanted to learn more about the impact of the investment my parents (Charline and Red McCombs of San Antonio) had made in MD Anderson years ago. I came on campus visits, liked what I saw and wanted to volunteer.

What has been most rewarding in almost a decade of volunteering on behalf of MD Anderson?
I’m inspired by watching professionals direct their expertise and passion to a common mission in a way that is changing lives every day. I’m proud of the genuine concern, courtesy and exceptional care extended by every single staff member to each and every person who walks through MD Anderson’s doors.

Why are you committed to Making Cancer History®?
I don’t want my children or grandchildren to experience the devastation and destruction caused by cancer.

Education:
• Bachelor of Arts in Spanish and religion, Duke University
• Post-graduate work in education, Trinity University
• Post-graduate work in business, The McCombs School of Business at The University of Texas at Austin

Board of Visitors Service:
• Vice Chair (current)
• Member, Executive Committee
• Chair, Clinical Business, Enterprise and Innovation Advisory Group
• Co-chair, 75th Anniversary Gala Committee
• Member, Events Committee
• Chair, Membership Committee
A simple shave turned Christopher Damico’s life upside down.

“I was shaving my neck when I felt a lump that was out of place,” says Damico. “I thought it was a swollen gland, but the lump didn’t go away. I had it checked out and, long story short, that lump was a lymph node to which cancer had spread from somewhere in my head and neck.”

The 45-year-old husband and father of three was floored when he received a stage IV diagnosis.

“I didn’t think I had any of the classic risk factors of head and neck cancer. I never smoked, I didn’t chew tobacco and I wasn’t a heavy drinker,” he says. “It turns out, in fact, I did have a significant risk factor: exposure to the human papillomavirus (HPV).”

About 80% of people — men and women — will at some point be infected with HPV.

“Virtually everyone, including young men and boys, will be exposed to HPV,” says Erich Sturgis, M.D., professor, Head and Neck Surgery. “That puts them at risk for developing these types of throat cancers.”

“I looked for the best head and neck treatment centers in the nation,” says Damico, who lives in Los Angeles, California. “MD Anderson was at the top of that list.”

After meeting with Sturgis and Adam Garden, M.D., professor, Radiation Oncology, he returned home to weigh his options.

“I was looking for a place that knew how to deal with my treatment when and if things went sideways, a place that could help me if I had to go from Plan A to Plan B to Plan C,” Damico says. “That is when expertise matters, and that type of expertise only comes with the experience and knowledge that exists at a place like MD Anderson.”

Throughout his cancer journey, Damico flew back and forth weekly from Los Angeles to Houston for radiation and chemotherapy so that he could spend the weekends back home with family. He quickly grew more interested in what was happening in his body — the biology, chemistry and physics of the treatment.

“Even after my treatment, when I’d come to Houston for quarterly or semi-annual checkups, that interest continued in discussions with Dr. Sturgis,” Damico says. “I became fascinated with the idea that vaccines like Gardasil could be used to stop cancers from developing in the first place.”

Damico’s cancer journey continues post-treatment through his advocacy and determination to raise awareness of HPV-related cancers. He’s created the Susan and Christopher Damico Chair for the benefit of the Department of Head and Neck Surgery in support of the HPV-Related Cancers Moon Shot™ team, begun serving as a patient advocate for MD Anderson’s National Cancer Institute-funded SPORE (Specialized Programs of Research Excellence) grant for HPV-related diseases and joined the MD Anderson Cancer Center Board of Visitors.

“We have a real opportunity to eradicate these cancers for our children’s generation,” says Sturgis. “Mr. Damico’s support is a significant help in advancing these efforts, from raising awareness in the public to educating policy makers about the problem of HPV.”
Peace Sullivan has never set foot inside MD Anderson. But despite the fact that she lives more than 1,100 miles away in Miami, Florida, Sullivan holds a special place in her heart for the institution. "My daughter-in-law went to MD Anderson when she was diagnosed with breast cancer at the age of 25," she says. "Other institutions had only negative news for her, but thank heaven she went to Texas. Ten years later, she has two beautiful children."

When Sullivan’s grandson was diagnosed with leukemia, she came up with a novel idea. “I was most taken by these unmet needs people were experiencing that nobody would think about,” says Sullivan. “For example, there was a play area for the children to enjoy, but it would have been nice if every child could have an iPad or individual toy for those very long days of chemotherapy treatment.”

When Sullivan’s grandson was diagnosed with leukemia, she came up with a novel idea. “I was most taken by these unmet needs people were experiencing that nobody would think about,” says Sullivan. “For example, there was a play area for the children to enjoy, but it would have been nice if every child could have an iPad or individual toy for those very long days of chemotherapy treatment.”

Working with the Department of Social Work at MD Anderson, Sullivan made a $100,000-plus gift dedicated to supporting unthought-of needs of cancer patients and their families.

“We’ve got the very best physicians. We know our patients are getting very good medical care,” says Margaret Meyer, director, Social Work. “But we also want to ensure that they’ve got all of the other support to help get them through the process. That’s where social work comes in.”

Sullivan’s fund already is being put to good use. In the short time that it’s been available, it’s been used to:

• purchase formula for feeding tubes necessitated by surgery for a head and neck cancer survivor
• help cover a breast cancer survivor’s bills while she was out of work for surgery
• help cover a clinical trial patient’s rent
• help a breast cancer survivor make an emergency mortgage payment that prevented her from losing her home

“This gift is truly a gift beyond gold,” says Carmella Wygant, a social work counselor at MD Anderson. “These families see $100 or $200, but they feel like it’s half a million. They don’t feel alone anymore because they see that someone cares. It’s really powerful.” Sullivan hopes that her gift might inspire others in the long run.

“We hope, in a small way, this fund might make that part just a little bit easier.”

— PEACE SULLIVAN

“When people are so overwhelmed by an illness like cancer, it’s very hard to think clearly and work out the other details of your life,” she says. “I hope, in a small way, this fund might make that part just a little bit easier.”

$100,000 gift supports patients’ unthought-of needs

BY ALLISON SCHAFFER

Peace Sullivan
SURVIVORS SAY

KARLEE STEELE, of Austin, is a three-time cancer survivor. She enjoys hiking and fishing with her son, Quade, 11. She has been with Cox Media Group for 10 years, first in El Paso and now in Austin, where she is a sales manager.

Whether it’s the first, or in my case, third diagnosis, the words ‘You have cancer’ are hard to hear. My first cancer diagnosis was in 2011. I had just moved to Austin with my son, when I learned I had stage II melanoma on my leg. After two surgeries, a sentinel node biopsy and clear margins, I needed a skin check every three months.

Two years later, a new mole appeared on my shoulder: stage I melanoma. The cancerous area was removed, and I received a clear report.

A year and a half later, I found a swollen node under my arm. A surgeon in Austin did a needle biopsy. It came back negative, but I still wanted it out. It was stage III melanoma. I was stunned. I eat well and exercise six days a week. I take pride in living a healthful life.

The ‘big cancer’ originated from my second melanoma, traveling into my lymph nodes, where it stayed silent for almost two years.

I wanted to be at the best cancer center in the world, with access to the latest melanoma treatment advancements. At MD Anderson, I made a plan with my oncology team to beat this ‘silent killer’ and soon underwent surgery.

Next I enrolled in an immunotherapy vaccine clinical trial. Its objectives were accomplished: It taught my body’s T cells to recognize and fight against melanoma in the future.

I’m forever grateful to MD Anderson and its wonderful team. My son and I continue to fish and hike. And I can live to see him develop into a fine young man.

Promise invites cancer survivors to share their reflections. Email promise@mdanderson.org.
In January 2016, my wife, Melissa, was diagnosed with synovial sarcoma, a form of soft tissue cancer. Given the disease’s rarity, we sought opinions from three hospitals. After deciding that MD Anderson was best for her, we met with Dr. Dejka Araujo, associate professor of Sarcoma Medical Oncology, who told us, ‘I have a plan for you.’ I can’t begin to express how meaningful those words are.

We made a commitment to Dr. Araujo and MD Anderson to defeat this disease. During Melissa’s chemotherapy, we commuted every 10 days to Houston, staying for a week and then returning home. We’ve walked through Hobby Airport more than 50 times in the past 12 months.

Dr. Araujo stuck with us, and we stuck with the plan. In May 2016, Melissa completed six rounds of chemotherapy. In June, we were told there was a new immunotherapy clinical trial for synovial sarcoma, one of the first breaks in treating sarcoma in almost 30 years, and that Melissa was eligible. In August, we went back to MD Anderson for her apheresis. We waited for her T cells to be ready, and they were reinfused on Dec. 5.

Melissa is the first sarcoma patient at MD Anderson to participate in this trial. Typically, synovial sarcoma is found in the joints. Melissa’s is in the pleural lining of her right lung. They say she is only one of 200 known cases in the world.

Dr. Araujo is giving us hope that we can win. We’ve made a choice that fear will not change the way we live. Melissa’s goal is to beat sarcoma and be on a billboard showing the world that she is winning, that cancer can’t get you down and something can be done.